Document Detail


Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma.
MedLine Citation:
PMID:  20066519     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Podoplanin, a mucin-type transmembrane glycoprotein, is thought to be one of the cancer stem cell markers for squamous-cell carcinoma of the vulva. The objectives of the present study were to examine the role of podoplanin in esophageal squamous-cell carcinoma (ESCC). METHODS: Expression of podoplanin was examined immunohistochemically in 61 cases of ESCC that had not been treated with chemotherapy or radiotherapy before surgery. Because cancer stem-cell quantities have been reported to increase with chemotherapy and radiotherapy, cases in patients who did not receive such prior therapies were included in this study. Cases with >10% tumor cells showing signals for podoplanin were categorized as podoplanin high, and the others were classified as podoplanin low. The effects of podoplanin on the behavior of cancer cells were evaluated in ESCC cell lines in which podoplanin expression was knocked down. RESULTS: To examine whether podoplanin could be used as a cancer stem cell marker for ESCC, podoplanin-positive and podoplanin-negative fractions were sorted separately from the ESCC cell line and cultured. Podoplanin-positive ESCC cells yielded both podoplanin-positive and podoplanin-negative cells, whereas few cells were obtained from podoplanin-negative ESCC cells. When podoplanin expression was knocked down, ESCC cell lines became vulnerable to anticancer drugs and showed defective invasion and tumorigenic activities. Nineteen (31.1%) of 61 cases were categorized as podoplanin high. Podoplanin-high cases were correlated with T category, stage of disease, lymphatic and vascular invasion, recurrence, and prognosis of patients. Podoplanin-low cases showed better overall and disease-free survival. CONCLUSIONS: There is a role for podoplanin in tumorigenesis and malignant progression in ESCC.
Authors:
Nur Rahadiani; Jun-ichiro Ikeda; Tomoki Makino; Tian Tian; Ying Qiu; Suhana Mamat; Yi Wang; Yuichiro Doki; Katsuyuki Aozasa; Eiichi Morii
Related Documents :
1189919 - Deoxyribonucleic acid content in the laryngeal mucosa with special reference to polyplo...
18065959 - Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
16273259 - Complex formations involving both sp-1 and sp-3 at the transcriptional regulatory seque...
2831179 - Dry mass, dna and non-histone protein determinations in lung cancer cells.
10211549 - Modulating effect of resveratrol and quercetin on oral cancer cell growth and prolifera...
8625559 - Cultured kaposi's sarcoma tumor cells fail to stimulate t cell proliferation.
23555919 - Pseudomonas aeruginosa cytotoxicity is attenuated at high cell density and associated w...
22919479 - Concurrent dual contrast for cellular magnetic resonance imaging using gadolinium oxide...
16916219 - Global gene expression analyses of mouse fibroblast l929 cells exposed to ic50 mma by d...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-01-12
Journal Detail:
Title:  Annals of surgical oncology     Volume:  17     ISSN:  1534-4681     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-20     Completed Date:  2010-07-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1311-23     Citation Subset:  IM    
Affiliation:
Department of Pathology, Osaka University, Graduate School of Medicine, Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Animals
Antineoplastic Agents / pharmacology
Apoptosis / drug effects
Blotting, Western
Carcinoma, Squamous Cell / drug therapy,  metabolism*,  pathology
Cell Movement
Cell Proliferation / drug effects
Colony-Forming Units Assay
Esophageal Neoplasms / drug therapy,  metabolism*,  pathology
Female
Flow Cytometry
Gene Silencing / physiology
Humans
Immunoenzyme Techniques
Male
Membrane Glycoproteins / physiology*
Mice
Mice, Inbred NOD
Mice, SCID
Middle Aged
RNA, Messenger / genetics,  metabolism
RNA, Small Interfering / pharmacology
Reverse Transcriptase Polymerase Chain Reaction
Survival Rate
Tissue Array Analysis
Topotecan / pharmacology
Treatment Outcome
Tumor Cells, Cultured
Tumor Markers, Biological / genetics,  metabolism*
Xenograft Model Antitumor Assays
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Membrane Glycoproteins; 0/PDPN protein, human; 0/RNA, Messenger; 0/RNA, Small Interfering; 0/Tumor Markers, Biological; 123948-87-8/Topotecan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma.
Next Document:  Anticancer effect of Lycium barbarum polysaccharides on colon cancer cells involves G0/G1 phase arre...